Strategic hospital partnerships JAX already collaborates with Hartford HealthCare, UConn Health, and state health authorities, and led SARS-CoV-2 testing initiatives, signaling strong appetite for joint research programs with hospitals and academic medical centers; target opportunities include translational genomics projects, contract research, data-sharing initiatives, and co-development of diagnostics or biomarkers.

Genomics expansion opportunities With leadership in genomic medicine and ongoing validation of methylome profiling at UConn Health, JAX represents a pipeline for external sequencing, methylation analysis, data analytics, and translational genomics collaborations—ideal for CRO-like partnerships with universities or biopharma.

Grant management opportunities The grant activity from The Michael J. Fox Foundation demonstrates active fundraising and grant management needs; given JAX uses Salesforce and other admin tools, there is potential to upsell advanced CRM, grant lifecycle management, dashboards and donor reporting to optimize grant capture and impact communication.

Global licensing prospects JAX's international footprint, including JAX Japan and cross-border webinars with SMC Laboratories, points to licensing and tech-transfer opportunities, including co-development of emerging platforms such as the skin micropatch and other genomic technologies with global partners.

Non-invasive tech opportunities Non-invasive skin micropatch development signals interest in medtech and diagnostics collaborations and regulatory-ready prototyping; there is potential to engage with biotech and medical device firms for joint R&D, clinical collaborations, and data analytics support around diagnostic readouts.